Last reviewed · How we verify
YTTRIUM CHLORIDE Y-90
At a glance
| Generic name | YTTRIUM CHLORIDE Y-90 |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2003 |
Approved indications
Common side effects
Key clinical trials
- Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant (PHASE1, PHASE2)
- Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL (PHASE2)
- Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma (PHASE2)
- Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma (PHASE2)
- Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery (PHASE3)
- Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YTTRIUM CHLORIDE Y-90 CI brief — competitive landscape report
- YTTRIUM CHLORIDE Y-90 updates RSS · CI watch RSS